Thomas T. MacDonald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas T. MacDonald has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Monteleone
6 shared publicationsGad Frankel
School of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD,1 Centre for Molecular Microbiology and Infection, Department of Biochemistry, Imperial College of Science, Technology and Medicine, London SW7 2AZ, United Kingdom2
3 shared publicationsGordon Dougan
School of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD,1 Centre for Molecular Microbiology and Infection, Department of Biochemistry, Imperial College of Science, Technology and Medicine, London SW7 2AZ, United Kingdom2
3 shared publications- Cameron Paul Simmons
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford
2 shared publications Catriona McKenzie
2 shared publications- Mona Bajaj-Elliott
University College London
2 shared publications
Latest Publications
- 31 October 2008
- Published by Elsevier in Gastroenterology
- Vol. 135 (4) , 1426-1427
Reply
- Open Access
Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn’s disease: Figure 1
Crohn’s disease appears to be caused by an excessive CD4+ T helper cell type I response directed against undefined antigens of the commensal bacterial flora.1 T cells from affected areas of Crohn’s disease mucosa produce enhanced amounts of interferon γ (IFN-γ) and tumour necrosis factor α. Other markers of Th1 cells, such as expression of the transcription factor T-bet, the high affinity β2 chain of the interleukin 12 (IL-12) receptor, and activated STAT4, all indicate that the mucosal environment in Crohn’s disease favours Th1 polarisation.1
Open AccessOsteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn’s disease: Figure 1
Crohn’s disease appears to be caused by an excessive CD4+ T helper cell type I response directed against undefined antigens of the commensal bacterial flora.1 T cells from affected areas of Crohn’s disease mucosa produce enhanced amounts of interferon γ (IFN-γ) and tumour necrosis factor α. Other markers of Th1 cells, such as expression of the transcription factor T-bet, the high affinity β2 chain of the interleukin 12 (IL-12) receptor, and activated STAT4, all indicate that the mucosal environment in Crohn’s disease favours Th1 polarisation.1
- 1 July 2005
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 29 (4S) , S118
Immunopathogenesis of Crohn's Disease
This review highlights the huge advances made in the understanding of Crohn's disease in the last 15 years. The pathogenic immune response in the gut wall is a highly polarised T helper cell type 1 response, probably directed against antigens of the commensal flora. There is marked over‐expression of pro‐inflammatory cytokines such as tumor necrosis factor (TNF)‐a and increased production of matrix degrading enzymes by fibroblasts and macrophages, which are probably responsible for ulceration and fistula formation. Crohn's disease runs in families and the susceptibility genes identified so far are associated with innate recognition of microbial products (Nod2) or epithelial barrier function (OCTN cation transporter genes and DLG5). Endogenous healing pathways mediated by transforming growth factor (TGF)‐β1 are inhibited because mucosal inflammatory cells express Smad7, the endogenous intracellular inhibitor of TGF‐β signalling. This makes it unlikely that enteral feeds containing TFG‐β are therapeutic by means of direct anti‐inflammatory effects, however TGF‐β may still be involved because it is a well known epithelial motogen and may promote mucosal healing, in synergy with changes in mucosal bacterial populations as a result of the change in the diet.
- 1 July 2005
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 29 (4S) , S118
Immunopathogenesis of Crohn's Disease
This review highlights the huge advances made in the understanding of Crohn's disease in the last 15 years. The pathogenic immune response in the gut wall is a highly polarised T helper cell type 1 response, probably directed against antigens of the commensal flora. There is marked over‐expression of pro‐inflammatory cytokines such as tumor necrosis factor (TNF)‐a and increased production of matrix degrading enzymes by fibroblasts and macrophages, which are probably responsible for ulceration and fistula formation. Crohn's disease runs in families and the susceptibility genes identified so far are associated with innate recognition of microbial products (Nod2) or epithelial barrier function (OCTN cation transporter genes and DLG5). Endogenous healing pathways mediated by transforming growth factor (TGF)‐β1 are inhibited because mucosal inflammatory cells express Smad7, the endogenous intracellular inhibitor of TGF‐β signalling. This makes it unlikely that enteral feeds containing TFG‐β are therapeutic by means of direct anti‐inflammatory effects, however TGF‐β may still be involved because it is a well known epithelial motogen and may promote mucosal healing, in synergy with changes in mucosal bacterial populations as a result of the change in the diet.
- Open Access
- 1 May 2005
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (9) , 5414-5422
Phenotypic Characterization of CD3−7+ Cells in Developing Human Intestine and an Analysis of Their Ability to Differentiate into T Cells
We have identified a large population of CD3−7+ cells in human fetal gut. Three- and four-color flow cytometry revealed a distinct surface Ag profile on this population; the majority were negative for CD4 and CD8, whereas most of the remainder expressed the CD8αα homodimer. In contrast about half of CD3+ cells expressed CD4 and half expressed CD8α. A large proportion of CD3−7+ cells expressed CD56, CD94, and CD161, and whereas CD3+ T cells also expressed CD161, they only rarely expressed CD56 or CD94. Further studies were conducted to determine whether the CD3−7+ cells have the potential to differentiate into CD3+ cells. About half of CD3−7+ cells contain intracellular CD3ε. Rearranged TCR γ-chains were detected in highly purified CD3−7+ cells as an early molecular sign of T cell commitment, and the pattern of rearrangement with V regions spliced to the most 5′ Jγ segment is reminiscent of early thymocyte differentiation. In reaggregate thymic organ cultures, CD3−7+ cells also gave rise to CD3+ T cells. Thus, we demonstrate that the CD3−7+ cells present in the human fetal gut display a distinct phenotype and are able to develop into CD3+ T cells.
- 1 May 2005
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (9) , 5414-5422
Open AccessPhenotypic Characterization of CD3−7+ Cells in Developing Human Intestine and an Analysis of Their Ability to Differentiate into T Cells
We have identified a large population of CD3−7+ cells in human fetal gut. Three- and four-color flow cytometry revealed a distinct surface Ag profile on this population; the majority were negative for CD4 and CD8, whereas most of the remainder expressed the CD8αα homodimer. In contrast about half of CD3+ cells expressed CD4 and half expressed CD8α. A large proportion of CD3−7+ cells expressed CD56, CD94, and CD161, and whereas CD3+ T cells also expressed CD161, they only rarely expressed CD56 or CD94. Further studies were conducted to determine whether the CD3−7+ cells have the potential to differentiate into CD3+ cells. About half of CD3−7+ cells contain intracellular CD3ε. Rearranged TCR γ-chains were detected in highly purified CD3−7+ cells as an early molecular sign of T cell commitment, and the pattern of rearrangement with V regions spliced to the most 5′ Jγ segment is reminiscent of early thymocyte differentiation. In reaggregate thymic organ cultures, CD3−7+ cells also gave rise to CD3+ T cells. Thus, we demonstrate that the CD3−7+ cells present in the human fetal gut display a distinct phenotype and are able to develop into CD3+ T cells.
- Open Access
- 1 May 2003
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (5) , 2960-2965
Binding of Intimin from EnteropathogenicEscherichia colito Lymphocytes and Its Functional Consequences
Intimin-conjugated fluorescent beads bind to spleen CD4 T cells and Peyer's patch, mesenteric lymph node, and cecal follicle lymphocytes, with less binding to lamina propria T cells and intraepithelial lymphocytes. Intimin costimulates proliferation of spleen CD4 T cells and cells from organized lymphoid tissues but does not costimulate cells from the lamina propria of normal or inflamed colon.
- 1 May 2003
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 71 (5) , 2960-2965
Open AccessBinding of Intimin from EnteropathogenicEscherichia colito Lymphocytes and Its Functional Consequences
Intimin-conjugated fluorescent beads bind to spleen CD4 T cells and Peyer's patch, mesenteric lymph node, and cecal follicle lymphocytes, with less binding to lamina propria T cells and intraepithelial lymphocytes. Intimin costimulates proliferation of spleen CD4 T cells and cells from organized lymphoid tissues but does not costimulate cells from the lamina propria of normal or inflamed colon.
- 1 January 2003
- Published by Elsevier in International Journal of Medical Microbiology
- Vol. 293 (1) , 87-93
Host defences to Citrobacter rodentium
- 1 January 2003
- Published by Elsevier in International Journal of Medical Microbiology
- Vol. 293 (1) , 87-93
Host defences to Citrobacter rodentium
- Open Access
Suppressor T cells, rebranded as regulatory T cells, emerge from the wilderness bearing surface markers
- 1 May 2002
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 34, S27-S30
The Biochemical Basis of Immune Enteropathy
- 1 May 2002
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 34, S27-S30
The Biochemical Basis of Immune Enteropathy
- Open Access
- 1 November 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (11) , 6651-6659
Critical Role for Tumor Necrosis Factor Alpha in Controlling the Number of Lumenal Pathogenic Bacteria and Immunopathology in Infectious Colitis
Infection of mice with the intestinal bacterial pathogenCitrobacter rodentiumresults in colonic mucosal hyperplasia and a local Th1 inflammatory response similar to that seen in mouse models of inflammatory bowel disease. In these latter models, and in patients with Crohn's disease, neutralization of tumor necrosis factor alpha (TNF-α) is of therapeutic benefit. Since there is no information on the role of TNF-α in either immunity to noninvasive bacterial pathogens or on the role of TNF-α in the immunopathology of infectious colitis, we investigatedC. rodentiuminfection in TNFRp55−/−mice. In TNFRp55−/−mice, there were higher colonic bacterial burdens, but the organisms were cleared at the same rate as C57BL/6 mice, showing that TNF-α is not needed for protective antibacterial immunity. The most striking feature of infection in TNFRp55−/−mice, however, was the markedly enhanced pathology, with increased mucosal weight and thickness, increased T-cell infiltrate, and a markedly greater mucosal Th1 response. Interleukin-12 p40 transcripts were markedly elevated inC. rodentium-infected TNFRp55−/−mice, and this was associated with enhanced mucosal STAT4 phosphorylation. TNF-α is not obligatory for protective immunity toC. rodentiumin mice; however, it appears to play some role in downregulating mucosal pathology and Th1 immune responses.
- 1 November 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (11) , 6651-6659
Open AccessCritical Role for Tumor Necrosis Factor Alpha in Controlling the Number of Lumenal Pathogenic Bacteria and Immunopathology in Infectious Colitis
Infection of mice with the intestinal bacterial pathogenCitrobacter rodentiumresults in colonic mucosal hyperplasia and a local Th1 inflammatory response similar to that seen in mouse models of inflammatory bowel disease. In these latter models, and in patients with Crohn's disease, neutralization of tumor necrosis factor alpha (TNF-α) is of therapeutic benefit. Since there is no information on the role of TNF-α in either immunity to noninvasive bacterial pathogens or on the role of TNF-α in the immunopathology of infectious colitis, we investigatedC. rodentiuminfection in TNFRp55−/−mice. In TNFRp55−/−mice, there were higher colonic bacterial burdens, but the organisms were cleared at the same rate as C57BL/6 mice, showing that TNF-α is not needed for protective antibacterial immunity. The most striking feature of infection in TNFRp55−/−mice, however, was the markedly enhanced pathology, with increased mucosal weight and thickness, increased T-cell infiltrate, and a markedly greater mucosal Th1 response. Interleukin-12 p40 transcripts were markedly elevated inC. rodentium-infected TNFRp55−/−mice, and this was associated with enhanced mucosal STAT4 phosphorylation. TNF-α is not obligatory for protective immunity toC. rodentiumin mice; however, it appears to play some role in downregulating mucosal pathology and Th1 immune responses.
- Open Access
- 15 August 2001
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 108 (4) , 601-609
Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease
TGF-β1 functions as a negative regulator of T cell immune responses, signaling to target cells using the Smad family of proteins. We show here that Smad7, an inhibitor of TGF-β1 signaling, is overexpressed in inflammatory bowel disease (IBD) mucosa and purified mucosal T cells. Both whole tissue and isolated cells exhibit defective signaling through this pathway, as measured by phospho-Smad3 immunoreactivity. Specific antisense oligonucleotides for Smad7 reduce Smad7 protein expression in cells isolated from patients with IBD, permitting the cells to respond to exogenous TGF-β1. TGF-β1 cannot inhibit proinflammatory cytokine production in isolated lamina propria mononuclear cells from patients with Crohn disease (CD), but inhibition of Smad7 restores TGF-β1 signaling and enables TGF-β1 to inhibit cytokine production. In inflamed mucosal tissue explants from patients with CD, inhibition of Smad7 also restores p-Smad3 and decreases proinflammatory cytokine production, an effect that is partially blocked by anti–TGF-β1. These results show that Smad7 blockade of TGF-β1 signaling helps maintain the chronic production of proinflammatory cytokines that drives the inflammatory process in IBD and that inhibition of Smad7 enables endogenous TGF-β to downregulate this response.
- 15 August 2001
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 108 (4) , 601-609
Open AccessBlocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease
TGF-β1 functions as a negative regulator of T cell immune responses, signaling to target cells using the Smad family of proteins. We show here that Smad7, an inhibitor of TGF-β1 signaling, is overexpressed in inflammatory bowel disease (IBD) mucosa and purified mucosal T cells. Both whole tissue and isolated cells exhibit defective signaling through this pathway, as measured by phospho-Smad3 immunoreactivity. Specific antisense oligonucleotides for Smad7 reduce Smad7 protein expression in cells isolated from patients with IBD, permitting the cells to respond to exogenous TGF-β1. TGF-β1 cannot inhibit proinflammatory cytokine production in isolated lamina propria mononuclear cells from patients with Crohn disease (CD), but inhibition of Smad7 restores TGF-β1 signaling and enables TGF-β1 to inhibit cytokine production. In inflamed mucosal tissue explants from patients with CD, inhibition of Smad7 also restores p-Smad3 and decreases proinflammatory cytokine production, an effect that is partially blocked by anti–TGF-β1. These results show that Smad7 blockade of TGF-β1 signaling helps maintain the chronic production of proinflammatory cytokines that drives the inflammatory process in IBD and that inhibition of Smad7 enables endogenous TGF-β to downregulate this response.